Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 6 Neoplasms by Histologic Type 2 Neoplasms 2 Lymphoproliferative Disorders 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Lymphatic Diseases 2 Immune System Diseases 2 Gastro-enteropancreatic neuroendocrine tumor 2 AIDS-Related Complex 2 Urogenital Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Recurrence 1 Prostatic Diseases 1 Prostate Cancer Metastatic 1 Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1 Metastatic Neuroendocrine Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-Resistant Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Immunoproliferative Disorders 1

Interventions

pembrolizumab 7 lenvatinib 3 apatinib 3 Magnetic Resonance Spectroscopy 3 Imatinib Mesylate 3 Carboplatin 3 gallium 68 PSMA-11 2 Specimen Handling 2 Protons 2 Nivolumab 2 Epirubicin 2 Cisplatin 2 Axitinib 2 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 tislelizumab 1 regorafenib 1 enfortumab vedotin 1 cabozantinib 1 avelumab 1 anlotinib 1 amivantamab 1 abemaciclib 1 Tretinoin 1 Trastuzumab 1 Tablets 1 Sunitinib 1 Standard of Care 1 Radiotherapy, Intensity-Modulated 1 Radiosurgery 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Adenoid Cystic × Lutetium × Clear all

NCT06199453 2025-02-10

LuRM_ACC/2023

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 2 Withdrawn

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡